we have a drug, even many drugs, good for so many indications, to become a giant pharma, we are about to get billions in revenues.

$HTGM A penny with cash and increasing revenue.

Revenue will pour in.

As investors digest the revenue potential, either via approval for RETT, or partnership for AD and PD, the stock price will rise accordingly.

$PDD closed 12.62% higher on Monday after the company reported a 65% year-over-year growth in its third-quarter revenue.

$BCRX shows a strong growth in Revenue.

$BCRX shows a strong growth in Revenue.

$BCRX shows a strong growth in Revenue.

We have a revenue generating drug thats just achieved 105% YoY growth.

Company had revenue and cash both in the current market much better than most bios out there.

but interesting From an Orladeyo standpoint, they are setting themselves up for a revenue beat next year.

Streamlined presentation (even nicer graphics), focus on revenue through 2039 with Orla, moving on from 9930, simple plan (we’ve been there before and lessons were learned) for 10013.

$BCRX so they hit their Q4 numbers, had stellar phase IA results and guided for a 70Mil increase in revenue in 202e.

A near-term positive catalyst could be a surprise revenue beat.

Solid growth revenue guaranteed !

company is actually doing spectacular and 190B+ in revenues next year.

On an annual basis, analysts expect healthy growth of 35% year-over-year.

In 2023, we believe we have a clear path to reaccelerate our revenue growth, and we are now well positioned to make use of the opportunities that China’s economic recovery offers us,” said Robin Li, Co-founder and CEO of Baidu.

$BABA shows a strong growth in Revenue.

$BABA $BIDU Huge revenue growth !

$BABA shows a strong growth in Revenue.

$BABA shows a strong growth in Revenue.

$BABA: The Revenue has been growing by 40.06% on average over the past 5 years.

$BABA $BIDU $PLTR $SNAP $TDOC These are deep intrinsic value stocks with strong BS Revenue EBITDA Cash Flow Industry Leaders and Able Leadership !